HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.1433
https://www.valueinhealthjournal.com/article/S1098-3015(23)01533-4/fulltext
Title :
HTA4 Pembrolizumab Vs. Standard of Care Chemotherapy As First-Line Treatment for Advanced Non-Small Cell Lung Cancer with High Pd-L1 Expression Levels: A Cost-Utility Analysis from the Ontario, Canada Public Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01533-4&doi=10.1016/j.jval.2023.03.1433
First page :
Section Title :
Open access? :
No
Section Order :
10837